Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Calidi Biotherapeutics, Inc.
Calidi to Effect Reverse Stock Split
July 05, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
June 27, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
June 11, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
June 10, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
June 03, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
May 31, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
May 14, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
May 01, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
April 23, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
April 19, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
April 16, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
April 09, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
March 15, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
March 11, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
February 12, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
January 08, 2024
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
December 13, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
December 12, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
November 20, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results
November 14, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
November 03, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
November 01, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
October 30, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
October 10, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
CLDI
Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
September 13, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
September 12, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients
July 18, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
June 23, 2023
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Tickers
FLAG
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs
December 13, 2022
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit
December 06, 2022
From
Calidi Biotherapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.